Similar articles

• The duty to disclose adverse clinical trial results.

  Liao SM, Sheehan M, Clarke S. Liao SM, et al. Am J Bioeth. 2009 Aug;9(8):24-32. doi: 10.1080/15265160902984988. Am J Bioeth. 2009. PMID: 19998154
• Disclosing clinical trial results: publicity, significance and independence.

  Liao SM, Sheehan M, Clarke S. Liao SM, et al. Am J Bioeth. 2009 Aug;9(8):W3-5. doi: 10.1080/15265160903088151. Am J Bioeth. 2009. PMID: 19998144 No abstract available.
• Respecting participant autonomy and the disclosure of clinical trial results.

  Oakley J. Oakley J. Am J Bioeth. 2009 Aug;9(8):38. doi: 10.1080/15265160902979806. Am J Bioeth. 2009. PMID: 19998158 No abstract available.
• Conflict of interest and informed consent in industry-sponsored clinical trials.

  Shimm DS, Spece RG Jr. Shimm DS, et al. J Leg Med. 1991 Dec;12(4):477-513. doi: 10.1080/01947649109510865. J Leg Med. 1991. PMID: 1800586 Review. No abstract available.
• Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.

  Anderson DC, Gomez-Mancilla B, Spear BB, Barnes DM, Cheeseman K, Shaw PM, Friedman J, McCarthy A, Brazell C, Ray SC, McHale D, Hashimoto L, Sandbrink R, Watson ML, Salerno RA, Cohen N, Lister CE; Pharmacogenetics Working Group. Anderson DC, et al. Pharmacogenomics J. 2002;2(5):284-92. doi: 10.1038/sj.tpj.6500131. Pharmacogenomics J. 2002. PMID: 12439734 Review. No abstract available.